GlassScriptPhysician profile
Fasika Aberra
NPI 1134480858
$2,419.56
in general payments reported to CMS, 2019-2025
27 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.01 · 2022: $553 · 2023: $329 · 2024: $634 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.43 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $643.96 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $564.74 | 2021-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $174.87 | 2022 | |
| Boston Scientific Corporation | $153.90 | 2025 | General - Biliary Devices, General - Endochoice |
| Pfizer INC. | $137.80 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Amgen INC. | $72.58 | 2025 | Tezspire, Repatha |
| Madrigal Pharmaceuticals | $57.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.34 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $45.62 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $41.69 | 2025 | Korlym |
| Genzyme Corporation | $41.61 | 2023-2025 | |
| Astellas Pharma US INC | $34.31 | 2025 | Cresemba |
| Celgene Corporation | $33.63 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $31.14 | 2023 | Cimzia, Clenpiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $21.74 | 2025 | |
| Merck Sharp & Dohme LLC | $20.78 | 2023 | Verquvo |
| Medtronic, INC. | $18.45 | 2022 | |
| Braintree Laboratories, INC. | $17.85 | 2024 | Sutab, Suflave |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2024 | |
| Abbott Laboratories | $16.65 | 2025 | Infinity |
| Janssen Pharmaceuticals, INC | $16.58 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $15.78 | 2023 | Dupixent |
| Novo Nordisk INC | $14.83 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.86 | 2024 | Voquezna |
| Sandoz INC. | $13.64 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fasika Aberra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.